Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,804 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus - Type 1 Clear all
Recruiting Not applicable Interventional

Discovery Diabetes

NCT07116434
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Discovery Program
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 17, 2026, 7:34 PM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

NCT06618612
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, PuraPly AM, PuraPly XT
Other · Device
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Clevland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 17, 2026, 7:34 PM EDT
Not listed Phase 2 Interventional

Ingested Interferon Alpha: Prolongation or Permanence of the "Honeymoon" Phase in Newly Diagnosed Type 1 Diabetes Mellitus

NCT00005665
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
interferon alpha
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
3 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

NCT00107107
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
25
States / cities
Tempe, Arizona • Concord, California • Fresno, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

NCT04436822
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Escondido, California • Santa Barbara, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Anti-Tac for Treatment of Leukemia

NCT00001941
View directory record Official record
Conditions
HTLV-I Infection, T Cell Leukemia
Interventions
daclizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Pramlintide in Adolescents With Type 1 Diabetes

NCT00842075
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
pramlintide
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

NCT02443155
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
NNC0114-0006, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
La Jolla, California • Northridge, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1Phase 2 Interventional

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

NCT00034255
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
INGAP Peptide
Drug
Lead sponsor
GMP Endotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Post Approval Study of the Eversense® Continuous Glucose Monitoring

NCT03908125
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Eversense® CGM System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Newport Beach, California • Englewood, Colorado • Fort Lauderdale, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Outpatient Control-to-Range: System and Monitoring Testing

NCT01578980
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Outpatient Control-to-Range
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

NCT01885208
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Pell City, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes

NCT01724190
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Vitamin D, Placebo
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 17, 2026, 7:34 PM EDT
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

NCT03624062
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MAS-1 adjuvanted Insulin B-chain
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Insul-In This Together Program for Adolescents With Type 1 Diabetes and Their Parents

NCT04589689
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insul-In This Together
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
12 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

Pancreatic Islet Cell Transplantation - A Novel Approach to Improve Islet Quality and Engraftment

NCT00530686
View directory record Official record
Conditions
Islet Cell Transplantation, Type 1 Diabetes
Interventions
Islet cell transplantation
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Technology-delivered Physical Activity Program for Adolescents With Type 1 Diabetes

NCT05319600
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Diabetes behavior change skills training, Physical activity promotion program
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
13 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 17, 2026, 7:34 PM EDT
Completed No phase listed Observational

Characteristics of Persons With an Eating Disorder and Type 1 Diabetes

NCT00945711
View directory record Official record
Conditions
Eating Disorder, Type 1 Diabetes
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
Not listed
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes

NCT04545567
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
RocketAP, USS Virginia
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 17, 2026, 7:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

NCT05626712
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
CELZ-201 Administration, Control Group
Biological · Other
Lead sponsor
Creative Medical Technology Holdings Inc
Industry
Eligibility
18 Years to 35 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 17, 2026, 7:34 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology 2.0 Adult and Adolescent Feasibility Study

NCT05014789
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Control-IQ technology 2.0
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
14 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 17, 2026, 7:34 PM EDT